How the brains behind YCombinator are trying to speed up Covid-19 studies
Sam Altman, who ran the startup accelerator YCombinator until last year, wanted to help fight the novel coronavirus outbreak. To Silicon Valley VC, that means funding biotech companies. But in meeting after meeting, founders mentioned the same stumbling block: Running clinical trials is a costly, time-consuming endeavor that makes developing drugs during a pandemic exceedingly difficult.
Altman’s answer is Project Covalence, a collaboration meant to speed up the process by using technology to recruit patients from afar, evaluate them remotely, and collect samples. As STAT’s Matthew Herper reports, the effort brings in TrialSpark, a health tech startup, and Mark Fishman, a Harvard Professor who was the founding president of the Novartis Institutes for Biomedical Research. The goal is collapse the standard timeframe for clinical trials.
“We're pushing ourselves … to think about things for Covid differently, more urgently,” Fishman said. “You know, this is not your standard trial. It has to be done quickly, but it has to be done well. And you've seen already the problems of trials being done or reported in a slipshod fashion.”
Read more.
Altman’s answer is Project Covalence, a collaboration meant to speed up the process by using technology to recruit patients from afar, evaluate them remotely, and collect samples. As STAT’s Matthew Herper reports, the effort brings in TrialSpark, a health tech startup, and Mark Fishman, a Harvard Professor who was the founding president of the Novartis Institutes for Biomedical Research. The goal is collapse the standard timeframe for clinical trials.
“We're pushing ourselves … to think about things for Covid differently, more urgently,” Fishman said. “You know, this is not your standard trial. It has to be done quickly, but it has to be done well. And you've seen already the problems of trials being done or reported in a slipshod fashion.”
Read more.
.png)
No hay comentarios:
Publicar un comentario